Kasia Siwek, Sanofi's country medical head for Australia and NZ, said, “At Sanofi, we are proud of our ongoing work with both the Australian clinical community and the government to broaden access to LIBTAYO as a first-line treatment for eligible Australians diagnosed with metastatic NSCLC. …
Sanofi welcomes new lung cancer listing for immune checkpoint inhibitor
April 4, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
BLS and Trexapharm move to bring TREXAVIVE to Australian patients
July 22, 2026 - - BioPharma -
Radiopharm Theranostics reports positive results in tumour trials
July 22, 2026 - - Australian Biotech -
Proteomics International and Healius team up to take Promarker tests national
July 22, 2026 - - Australian Biotech